Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
59 studies found for:    Temporal arteritis
Show Display Options
Rank Status Study
21 Recruiting Validation of a Diagnostic Algorithm of Giant Cell Arteritis
Condition: Giant Cell Arteritis
Intervention: Other: color Doppler ultrasound and TAB in case of CDU negative
22 Completed Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis
Conditions: Takayasu's Arteritis;   Giant Cell Arteritis;   Arteritis;   Vasculitis;   Aortitis
Intervention:
23 Recruiting Improving the Diagnosis and Prognostication of GCA Through the Novel Use of PET Scan and Immune Biomarkers
Condition: Giant Cell Arteritis
Intervention:
24 Completed MRI Superficial Temporal Artery
Condition: Temporal Arteritis
Intervention: Device: MRI
25 Recruiting Study of Phenotypic and Functional Characteristics of Regulatory T Lymphocytes in Horton's Disease
Condition: Horton's Disease
Intervention: Biological: Blood samples
26 Recruiting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu Arteritis
Intervention:
27 Enrolling by invitation VCRC Patient Contact Registry Patient-Reported Data Validation Study
Conditions: Behcet's Disease;   Churg-Strauss Syndrome;   Giant Cell Arteritis;   Wegener Granulomatosis;   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
Intervention:
28 Terminated Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels
Conditions: Coronary Artery Disease;   Inflammatory Response;   Atherosclerosis
Intervention: Dietary Supplement: eicosapentaenoic acid (EPA),
29 Completed Educational Needs of Patients With Systemic Vasculitis
Conditions: Behcet's Disease;   Churg-Strauss Syndrome;   Vasculitis, Central Nervous System;   Giant Cell Arteritis;   Wegener Granulomatosis;   Henoch-Schoenlein Purpura;   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
Intervention:
30 Not yet recruiting Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?
Conditions: Arthritis;   Vasculitis
Intervention:
31 Unknown  Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
Conditions: Purpura, Schoenlein-Henoch;   Graft Versus Host Disease;   Anemia, Hemolytic, Autoimmune;   Rheumatoid Arthritis;   Churg-Strauss Syndrome;   Hypersensitivity Vasculitis;   Wegener's Granulomatosis;   Systemic Lupus Erythematosus;   Giant Cell Arteritis;   Pure Red Cell Aplasia;   Juvenile Rheumatoid Arthritis;   Polyarteritis Nodosa;   Autoimmune Thrombocytopenic Purpura;   Takayasu Arteritis
Interventions: Drug: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: filgrastim;   Drug: methylprednisolone;   Drug: prednisone;   Procedure: Autologous Peripheral Blood Stem Cell Transplantation
32 Completed Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
Conditions: Rheumatoid Arthritis;   Polymyalgia Rheumatica;   Giant Cell Arteritis;   Polymyositis;   Wegener’s Granulomatosis
Intervention: Drug: Alendronate versus alfacalcidol (1-alpha OH vitamin D)
33 Withdrawn Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
Condition: Neovascular Age-related Macular Degeneration
Interventions: Drug: Aflibercept;   Drug: Triamcinolone Acetonide;   Drug: Verteporfin
34 Completed Impact of Vasculitis on Employment and Income
Conditions: Vasculitis;   Systemic Vasculitis;   Behcet's Disease;   CNS Vasculitis;   Cryoglobulinemic Vasculitis;   Eosinophilic Granulomatosis;   Temporal Arteritis;   Wegener Granulomatosis;   Henoch-Schoenlein Purpura;   Microscopic Polyangiitis;   Polyarteritis Nodosa (PAN);   Takayasu's Arteritis;   Urticarial Vasculitis
Intervention: Other: online questionnaire
35 Recruiting Interest of Medical Imaging in the Diagnostic Strategy Vis a Vis a Suspected Horton Disease
Condition: Horton Disease
Interventions: Radiation: Vascular tomodensitometry;   Other: Magnetic resonance angiography;   Other: Vascular ultrasonography;   Other: Retinal angiography;   Other: Retinal optical coherence tomography
36 Unknown  Study of the T CD8 Immune Response in Horton's Disease
Condition: Horton's Disease
Interventions: Other: Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment;   Other: 16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment;   Other: Blood sample drawn into a 5 mL dry tube;   Other: 16 blood samples drawn into 6 mL heparinized tubes
37 Recruiting One-Time DNA Study for Vasculitis
Conditions: Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss);   Giant Cell Arteritis;   Granulomatosis With Polyangiitis (Wegener's);   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
Intervention:
38 Unknown  Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Horton's Disease: Proof of Concept Study.
Condition: Horton's Disease
Intervention: Drug: corticoids+ tocilizumab 8mg/Kg/month
39 Not yet recruiting Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE
Condition: Polymyalgia Rheumatica
Interventions: Drug: Tocilizumab;   Drug: Placebo
40 Not yet recruiting Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica
Condition: Polymyalgia Rheumatica
Interventions: Drug: Sirukumab;   Drug: Placebo to match sirukumab;   Drug: Prednisone /Prednisone placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-59) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.